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Abstract 
The deep and periventricular white matter is preferentially affected in several neurological 
disorders, including cerebral small vessel disease (SVD) and multiple sclerosis (MS), 
suggesting that common pathogenic mechanisms may be involved in this injury.  Here we 
consider the potential pathogenic role of tissue hypoxia in lesion development, arising partly 
from the vascular anatomy of the affected white matter.  Specifically, these regions are 
supplied by a sparse vasculature fed by long, narrow end-arteries/arterioles that are 
vulnerable to oxygen desaturation if perfusion is reduced (as in SVD, MS and diabetes), or if 
the surrounding tissue is hypoxic (as in MS, at least).  The oxygen crisis is exacerbated by a 
local preponderance of veins, as these can become highly desaturated ‘sinks’ for oxygen that 
deplete it from surrounding tissues.  Additional haemodynamic deficiencies, including 
sluggish flow and impaired vasomotor reactivity and vessel compliance, further exacerbate 
oxygen insufficiency.  The cells most vulnerable to hypoxic damage, including 
oligodendrocytes, die first, resulting in demyelination.  Indeed, in pre-clinical models, 
demyelination is prevented if adequate oxygenation is maintained by raising inspired oxygen 
concentrations.  In agreement with this interpretation, there is a predilection of lesions for the 
anterior and occipital horns of the lateral ventricles, namely regions located at arterial 
watersheds, or border zones, known to be especially susceptible to hypoperfusion and 
hypoxia.  Finally, mitochondrial dysfunction due to genetic causes, as occurs in 
leukodystrophies, or due to free radical damage, as occurs in MS, will compound any energy 
insufficiency resulting from hypoxia.  Viewing lesion formation from the standpoint of tissue 
oxygenation not only reveals that lesion distribution is partly predictable, but may also 
inform new therapeutic strategies. 
 
Summary statement (for broad audience) 
The selective vulnerability of the parts of the brain to injury can give clues to pathological 
mechanisms.  We explore the role of inadequate oxygenation and selective cell death arising 
from the vascular anatomy, and consider the consequent therapeutic opportunities.   
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Introduction 
The periventricular and deep white matter is preferentially affected in a range of neurological 
disorders, notably small vessel disease (SVD) and multiple sclerosis (MS), but also including 
some leukodystrophies, mitochondrial diseases, and diabetes.  The fact that so many 
aetiologically distinct disorders cause lesions with similar topography suggests not only that 
these sites may be distinctly susceptible to insult, but also that lesion genesis may arise from 
shared mechanisms.  Here we note the known vulnerability of the periventricular white 
matter to ischaemia, and focus attention more specifically on an inadequacy of the oxygen 
supply to this region as the mechanism responsible for the white matter lesions.  We accept, 
of course, that ischaemia is a more profound insult than the hypoxia it causes, with an 
attendant reduction in the provision of glucose and other substrates, and a compromised 
removal of products such as carbon dioxide and lactate, and all these factors will contribute 
to the toxic milieu.  Indeed, other factors such as inflammation-mediated nitric oxide and 
superoxide may also play a role in lesion formation in intensely inflammatory diseases such 
as MS.  However, recent findings have revealed that even in intensely inflammatory lesions it 
is the paucity of adequate oxygen that is decisive in causing demyelination [1].  Indeed, the 
cells most vulnerable to the deleterious effects of tissue hypoxia are oligodendrocytes, which 
are selectively killed under hypoxaemic conditions, resulting in the observed pattern of 
demyelination.  Notably, this demyelination can be prevented by breathing oxygen-
supplemented ‘air’ (see below) [1].  This review focuses on the pivotal role of low oxygen (as 
distinct from ischaemia per se) in determining lesion formation and location, in the belief that 
this more precise focus may reveal the importance of particular types of therapy.  We draw 
evidence mainly from observations in SVD and MS, as these disorders have been the focus of 
much attention, and indeed a contribution from SVD to MS has been discussed [2].  The 
mechanisms we describe do not, of course, provide a universal description of lesion 
formation, nor could they because cerebral SVD and MS involve a range of disease processes 
e.g. [3;4].  Moreover, we recognise that SVD and MS are separate pathological entities, and 
do not suggest that the origins of the diseases, or their clinical manifestations, are the same.  
Rather, we address the common involvement of the periventricular and deep white matter in 
both to highlight how a lack of adequate oxygenation may play a role in each disease.  
Focusing on hypoxia may illuminate a pathogenic mechanism that plays a more important 
role in neurological disease than is currently appreciated.   
 
SVD and the tendency to periventricular lesions 
Cerebral SVD has been defined as “all pathological processes that affect the small vessels of 
the brain”, thereby encompassing a number of underlying mechanisms including 
arteriosclerosis, amyloid angiopathy, inflammatory vasculitis, and inherited mutations, 
among others [5].  How SVD results in tissue damage is not well understood, but both 
ischaemic and haemorrhagic causes have been recognized [5], together with breakdown of 
the blood-brain barrier [6], and activation of innate immune mechanisms [7].  SVD lesions 
occur preferentially in sub-cortical structures, such as in the cerebellar and brainstem white 
matter, the basal ganglia and thalamus, and, notably, the deep and periventricular white 
matter [8].  These white matter lesions, which appear hyperintense on MRI (termed 
leukoaraiosis), are most consistently found in the frontal and occipital horns of the 
periventricular white matter [9], and their likelihood decreases with distance from the 
ventricles [10].  Notably, the distribution of periventricular leukoaraiosis is similar even 
when caused by different pathological SVD mechanisms, suggesting that injury to the white 
matter arises from a regional vulnerability [9;11].  
 
MS and the tendency to periventricular lesions 
  
The most detailed examinations of white matter lesion location have been performed in the 
MS brain.  MS lesions are often described as having a semi-random distribution within the 
white matter, but in fact they have a clear predilection for certain areas, including the junction 
of the cortex and white matter [12], the spinal white matter tracts [13-15], the optic nerves 
[13;16;17], and, as with SVD, especially the periventricular white matter [12;18-20](figure 
1a).  Here we focus on the periventricular white matter as an exemplar which can reveal local 
cellular and vascular factors critical to lesion formation that may also be instrumental at other 
sites, but remain less obviously expressed.   
 
Why is the periventricular white matter vulnerable? 
The particular vulnerability of the dorsal periventricular white matter to lesion formation 
appears to be imposed by the anatomy of the arterial blood vessels, namely that the tissue is 
supplied by an array of long, narrow, end arteries/arterioles [12;21-23].  Each of these 
features, coupled with the fact that this region of the brain is poorly vascularized (figure 2a 
&b) [24], renders the integrity of the local oxygen supply precarious.  The arterioles are 
unusually long at approximately five centimetres in length, penetrating from the pial surface 
through the brain tissue to their periventricular destination (figure 2c).  Moreover, they have a 
very narrow diameter of only 100-200μm, even at their origins, making it ‘difficult’ for 
viscous blood to pass along the vessels: indeed, Poiseuielle’s law teaches that flow varies 
with the fourth power of the radius, and is thus substantially reduced by the diameter of 
narrow vessels.  The motive power for flow is provided by the gradient in blood pressure 
from the proximal to distal parts of the long vessels, so hypotension affecting cerebral arteries 
will disproportionately reduce perfusion and oxygenation of periventricular tissue as 
compared with other brain regions.  Furthermore, the periventricular arterioles are end-
arterioles that independently supply particular fields, imposing a limited capacity for 
compensatory collateral replacement if oxygen supply is impaired.  Moreover, with age, the 
penetrating arterioles can also become tortuous (reviewed in [25]).  Not only will this impose 
a higher imperative on maintaining blood pressure to preserve adequate perfusion [26], but it 
will also increase the opportunity for oxygen desaturation by impeding and slowing flow, 
thereby providing more time and surface area over which oxygen can be lost.   
 
However, perhaps the greatest problem associated with long, narrow arteries/arterioles is one 
that is less appreciated, namely that these are prone to substantial losses of oxygen through 
the arterial wall [27-32], a phenomenon that has been clearly illustrated in experiments 
exploring the consequences of inspiratory hypoxia on cerebral mitochondrial function [33;34] 
(figure 3).  Figure 3 shows how oxygen diffuses from arteries to sustain mitochondrial 
oxidative phosphorylation in the surrounding tissues (figure 3A &B), and the precise 
superimposition of mitochondrial FAD fluorescence with mitochondrial polarisation (figure 
3B).  These observations have been made in rodent cerebral arteries, and while rodent vessel 
walls are arguably thinner and presumably more permeable to oxygen than human arteries, 
this consideration must be balanced against the fact that human vessels are very much longer, 
permitting greater opportunity for oxygen depletion.  This opportunity is potentiated if 
surrounding brain tissue is hypoxic, as this steepens the gradient for oxygen diffusion from 
vasculature to tissue.  In health, diffusion gradients are low in the well-oxygenated brain, and 
oxygen loss is consequently small, but the MS brain is characterized by widespread tissue 
hypoxia (see below) and so the risk of significant blood de-oxygenation is much enhanced.  
In fact, this risk is greater still because the MS brain is also marked by a global slowing of 
cerebral blood flow (see below), which allows more time for de-oxygenation to occur.   
 
  
For the considerations above, the risk of detrimental blood deoxygenation is substantial, and 
this problem will typically be at its most severe within veins, which are plentiful in the 
periventricular white matter.  Different venules and veins have a heterogeneous oxygen 
concentration so that Vovenko, for example, found “A distinct difference in colour between 
separate streams of blood, the result of confluence of flows from small proximal venules, 
could be seen with the microscope.”, but despite this heterogeneity, “…all studied venules 
released oxygen to the tissue under normoxic conditions.” [30].  Thus, notably, veins 
normally act to supply oxygen to surrounding brain tissue [29;30;35], and this tissue is 
presumably dependent on the venous provision.  An indication that veins provide oxygen to 
tissue can be seen in figure 3b (arrows) in which the vein to the left is surrounded by a 
narrow halo.  Of course the halo is narrower than that around arteries, because the venular 
concentration of oxygen is less than that in arteries, but, nonetheless, venular oxygen is 
sustaining function in the mitochondria of the surrounding cells.  However, rather than 
functioning in such a supply capacity, veins containing highly de-oxygenated blood become 
sinks for oxygen [29], draining it from surrounding oligodendrocytes and axons and 
rendering these even more hypoxic.  These considerations can easily explain the well-known 
predilection for MS lesions to form around veins [13;36-43], now demonstrated in living 
patients [44-48].  Whereas early neuropathologists have understandably supposed that 
‘something bad leaks from veins’ to induce perivenular demyelination (see [49]), a more 
complete explanation includes the fact that something good, oxygen, can fail to leak from 
veins. 
 
Thus, a combination of deleterious conditions renders the periventricular white matter at 
severe risk of suffering hypoxia, and this risk will be exacerbated if other co-incident factors 
exist that promote it, such as infection, anaemia, sleep apnoea, low atmospheric oxygen 
pressures or increased altitude.   
 
The influence of vascular watersheds  
In addition to the vulnerability of the periventricular white matter in general, there is a 
specific vulnerability of the white matter at the anterior and occipital horns of the ventricles 
[18].  Indeed, 90% or more of MS patients have a lesion pinpointed at these specific locations 
(i.e. a lesion here is almost a certainty) establishing that lesion distribution is partly 
predictable.  In fact, the tendency of lesions to form precisely at the horns is as remarkable as 
the zero percent chance of a lesion in the immediately adjacent tissue: heat maps of lesion 
location reveal that, out of 1249 lesions, none occur at that location (figure 1b) [18].  The 
particular vulnerability of the anterior and posterior horns appears to arise due to the 
superimposition of another inherent attribute of their vascular anatomy, namely that these 
locations are at the very ends of three arterial territories, at the watershed (border zone) 
formed by the confluence of the anterior and middle cerebral arteries (ventriculopetal 
branches) and the lenticulostriate arteries (figure 1) [50;51].  This correlation between lesion 
location and vascular watersheds has been noted previously [12;18;19;22;23], and the 
concept may explain the predilection of MS lesions to form at other watersheds, including the 
optic nerves [17])[52;53], spinal cord [15;54-56], and between the various cerebral arteries 
[12;57].  Unsurprisingly, watersheds are distinguished by their susceptibility to hypoxia, and 
blood flow in cerebral border zones in healthy individuals is indeed significantly (p<0.001) 
lower than in non-border zone regions, with longer arterial transit times [57;58] (allowing 
more time for oxygen loss).  Accordingly, infarcts form selectively at watershed sites if 
global perfusion is impaired [59].   
 
  
When considering heat map distributions of lesions (figure 1) it is important to note that these 
maps may omit less severe lesions, or lesions effectively rendered invisible due to repair by 
remyelination.  Thus, Holland and colleagues [18] note that lesions are distributed more 
widely in early relapsing-remitting MS, but that they may persist in poorly perfused regions.  
In this way, the periventricular lesions shown on the maps may represent lesions that, due to 
their location, are either less well repaired, or rendered more severe with persistent damage.  
Accordingly, although remyelination can be extensive in MS, it occurs less commonly in the 
periventricular white matter [60].  Failure of remyelination may reflect the fact that the 
oligodendrocyte precursor cells required for remyelination can be especially vulnerable to 
hypoxia [61], or that repair mechanisms are ‘worn out’ by repeated challenges.  Experimental 
evidence against the latter possibility has been provided [62], but here the repeated 
demyelinating challenge was not inflammatory (it was effected by ethidium bromide) and so 
the number of precursor cells would probably not be depleted.   
 
The vulnerability of oligodendrocytes in watershed tissue is well illustrated by the 
demyelinating Pattern III lesion induced by the direct intraspinal injection of 
lipopolysaccharide in rodents [63-65].  Interestingly, this lesion selectively forms not at the 
site of lipopolysaccharide injection, but rather at a neighbouring vascular watershed in the 
spinal cord [1].  In contrast, demyelinating agents that are directly myelinolytic or 
oligodendrocyte-toxic form lesions centred on the site of injection [66-68], as expected.  The 
shift in location from the site of injection to the watershed, although subtle in terms of 
distance, reveals the vulnerability of the oligodendrocytes to hypoxia: it is not the 
lipopolysaccharide that kills the oligodendrocytes, but rather the tissue hypoxia which forms 
in response to the inflammation, and this is most severe within the watershed tissue.  In the 
rodent spinal cord, this watershed lies at the termination of three arterial supplies (two dorsal 
and one ventral artery) [69;70], and the human anatomy is closely similar.  It is therefore 
unsurprising that, in humans, systemic hypoperfusion also produces lesions due to 
spinovascular insufficiency in the same “endangered frontier zone” or watershed tissue [71].  
This region of the dorsal columns also shows a relative paucity of blood vessels [1].  
 
Patchy distribution of oxygen in normal brain due to vessel density & configuration 
It is notable that the oxygen concentration is far from homogeneous across even the normal 
healthy brain.  Instead, there exist steep gradients between vessels [72-74], such that tissues 
most proximal to arteries are marked by high oxygen levels [75], while niches between 
adjacent capillaries can fall to near anoxia [35;73;75;76].  The likelihood of such niches 
increases with reduced vascular density, and the periventricular white matter is inherently 
poorly vascularised [24].  Indeed, oligodendrocytes located only 35-40µm from a capillary 
become much more hypoxic than more proximal cells, and this vulnerability is easily 
exposed in animals breathing 10% oxygen [1].  Moreover, this vulnerability will increase in 
circumstances where the arterial/arteriolar blood is partly desaturated on its journey, as 
discussed above.  The consequences of such desaturation will be exacerbated in some vessels 
by the fact that at bifurcations the red cells preferentially enter the branch with the higher 
flow (phase separation and Fahraeus effects), so that after multiple bifurcations the vessel 
haematocrit can be quite heterogeneously distributed across the tissue, and some vessels are 
poorly provided with red cells [77;78].  The vessel haematocrit is also dynamic, because it 
will change as vessels change their diameter to satisfy local electrical (and other) demand.  
Capillary dysfunction and the associated disruption of capillary flow patterns also limits the 
extraction efficacy of oxygen [79], further contributing to tissue oxygen insufficiency.  The 
resulting mosaic distribution of oxygen concentrations even in the normal brain renders 
particular cells and micro-niches inherently susceptible to hypoxia, i.e. they habitually live 
  
near a ‘cliff edge’, and the superimposition of additional deleterious factors can topple cells 
over the edge into fatally low oxygen levels.  The most vulnerable cells will die first, 
principally the oligodendrocytes (see below).  In accord with these considerations, larger MS 
lesions tend to be further from blood vessels large enough to be detectable by MRI, and the 
vessels nearest to the lesions tend to be of smaller diameter, consistent with the lesions 
having a hypoxic aetiology [80].   
 
An interesting consideration is that veins are fed by blood from different capillary territories 
and if some of these are less affected by hypoxia the veins to which they drain can have a 
higher oxygen concentration than the tissue through which they pass.  In this case they will 
instead supply oxygen to the hypoxic tissue (as normal), providing an explanation for why 
Pattern III demyelinating lesions in MS often contain a thin rim of preserved myelination 
around veins despite demyelination beyond that border [4;81].   
 
Vessels in both SVD and MS can exhibit a widened perivascular space, which can contain 
inflammatory cells.  Both these features will exacerbate the hypoxia experienced by the 
adjacent white matter.  First, the widened space may partly be at the expense of the diameter 
of the lumen, which will clearly impair flow.  Additionally, the presence of the perivascular 
fluid imposes an impediment to oxygen diffusion from the blood to the tissue.  The additional 
presence of perivascular cells (as occurs in SVD and the ‘perivascular cuff’ of MS) will 
further impede oxygen diffusion.  Moreover, these cells may also consume oxygen 
themselves, reducing supply to adjacent tissues.   
 
In summary, several factors render particular brain regions severely and selectively 
vulnerable to hypoxia.  The periventricular white matter exemplifies this: it is inherently 
poorly vascularized, and its limited vascular supply consists of long, fine, end-arterioles that 
are vulnerable to loss of oxygen by diffusion through vessel walls, particularly if the brain is 
hypoxic and vascular flow is slow.  The paucity of anastomoses between local arterioles 
exacerbates this by rendering their distal irrigation fields at increased risk of inadequate 
perfusion.  Moreover, portions of the periventricular white matter are located at poorly-
perfused, ‘at risk’ watershed regions at the boundaries of converging arterial territories, 
which increases the probability of inadequate oxygenation.  The veins will contain 
particularly de-oxygenated blood, and cells and tissue dependent on venular oxygen will 
therefore become severely hypoxic, resulting in selective oligodendrocyte death (see below) 
and demyelination.  More severe hypoxia will cause axonal degeneration.   
 
Haemodynamic deficiencies imposed by SVD & MS 
The vulnerabilities to inadequate tissue oxygenation imposed by the brain’s inherent vascular 
architecture may lie dormant for the lifetime of an individual, but they are likely to be 
exposed from time to time by adverse events, such as infections and other disease, or simply 
by age-related pathology, like SVD, that have deleterious haemodynamic consequences.  
Here we explore the extent of haemodynamic alterations present in SVD and MS, like 
hypoperfusion and vasomotor reactivity, in order to draw attention to their possible 
contributions to lesion genesis. 
 
Haemodynamic consequences of SVD 
Arteriosclerosis of cerebral vessels (Type 1 SVD) [5] causes partial occlusion of the vessel 
lumen, and the resulting hypoperfusion corresponds with the severity of ischaemic damage in 
deep and “irregular” periventricular lesions [82], suggesting that reduced tissue perfusion 
(and by extension reduced oxygenation), may be pathogenic in the white matter lesions of 
  
SVD.  This point has been examined by Shi and colleagues, who systematically reviewed 34 
cross-sectional and 4 longitudinal studies regarding cerebral blood flow in SVD to clarify any 
cause-and-effect relationship.  Meta-analysis of 24 cross-sectional studies revealed that 
higher burdens of white matter hyperintensities (WMH) correlate with lower cerebral blood 
flow, globally and in most grey and white matter regions [83].  Evidently, there is a close 
association between global hypoperfusion and white matter damage, but our understanding of 
the cause and effect relationship of these phenomena remains incomplete.  This review 
focuses on the mechanisms by which falling blood flow can precipitate white matter damage 
by impairing its oxygen delivery.  These mechanisms necessitate declining blood flow to 
precede white matter damage, as indeed occurs in the periventricular white matter [84]. Here, 
reductions in global cerebral blood flow over time correlate with the progression of 
periventricular WMH loads [84].  Intriguingly, the same is not true of the deep white matter, 
where declining global blood flow does not impact the risk of lesion development [84].  This 
discrepancy suggests that these regions are differentially predisposed to lesion formation by 
insufficient blood flow.  This interpretation is supported by analysis of regional (rather than 
global) blood flow.  In patients with ischaemic leukoaraiosis, reductions to cerebral blood 
flow occur preferentially in the periventricular normal appearing white matter, remaining 
normal in the grey matter and deep normal appearing white matter [85].  This regional 
vulnerability is not surprising given the unique vascular architecture of the periventricular 
white matter (outlined above).  Moreover, just as falling blood flow can precipitate white 
matter damage by impairing its oxygen supply, so too may vascular deficits arise as a result 
of WM damage, given that damaged tissue is likely to be non-functional and therefore have 
reduced oxygen demands.  Once white matter becomes damaged by an initial perfusion 
deficit, further vascular compromise might ensue, exacerbating the original insult.  
 
An early precursor to arteriosclerosis, endothelial dysfunction also predisposes to 
haemodynamic alterations in the form of aberrant vasomotor reactivity, an important auto-
regulatory haemodynamic control mechanism.  Indeed, the degree of endothelial dysfunction 
in patients with SVD is associated with the severity of WMH loads and cerebral microbleeds 
[86].  Specifically, endothelial-mediated vasodilation correlates inversely with WMH 
volume, suggesting that endothelial dysfunction, and therefore altered vascular 
autoregulation, may be pathogenic in cerebral SVD [87].  In agreement, cerebral vasomotor 
reactivity is inversely associated with total white matter lesion loads, and, unsurprisingly, 
periventricular lesions exhibit the strongest correlations [88;89].  In fact, in some SVD 
patients impaired vasomotor reactivity (i.e. impaired dynamic control of blood flow) may be 
a better predictor of disease severity than resting cerebral blood flow [89].  
 
Venous collagenosis, the type 5 SVD characterised by veins and venules with pathologically 
thickened walls [5], will also impair local haemodynamics.  These stenotic venules, like their 
sclerosed arteriolar counterparts, will impair flow.  Thus, arteriolar and venular pathology 
may synergise in promoting the conditions for tissue hypoxia.  Indeed, the extent of venous 
collagenosis correlates with the severity of leukoaraiosis, suggesting venous disease 
(stenosis/occlusion) participates in white matter pathology [90].  In confluent periventricular 
lesions (caps and halos), “large tortuous venules, but not arteriolosclerotic” changes are 
observed, and myelin loss is most severe around such venous structures [82].  
 
In SVD the vascular and white matter pathology progress hand in hand over decades and it is 
therefore difficult to discern which pathology is primary, and which secondary.  The 
sequence of events may therefore be easier to determine in MS, where the genesis of 
individual lesions occurs over a shorter time scale, and in younger patients.   
  
 
Haemodynamic consequences of MS 
The MS brain is affected by a number of haemodynamic disturbances that will tend to expose 
any inherent vulnerabilities to tissue hypoxia.  Most importantly, a broad consensus has 
arisen that there is a widespread reduction in cerebral blood flow in MS (reviewed in 
[91;92]), although this view has been challenged [93] and some reports describe increases in 
white matter flow alongside reductions in the grey matter [94;95].  Nonetheless, the current 
balance of evidence favours a significant reduction in flow in both the grey and white matter 
in relapsing-remitting [20;96-104] and primary-progressive MS [102;103;105], as well as a 
disability-associated reduction in the thalamus [106] see also [107].  A significant reduction 
in cortical blood flow in the absence of structural differences has also been reported in 
cognitively impaired people with MS [108;109].   
 
Of particular interest are observations on blood flow before disease is advanced in MS, such 
as in patients with clinically isolated syndrome and in normal appearing white matter, where 
clues may be found concerning factors contributing to the initiation or advance of the disease.  
For example, decreased perfusion has been reported in both the corpus callosum [110], 
normal appearing white matter [96;100], and deep grey matter [96] in clinically isolated 
syndrome, suggesting that reduced perfusion is a primary event in disease development, 
rather than a secondary response to reduced tissue demand [91;110] (see also [111]).  The 
reduced flow in the normal appearing white matter and deep grey matter occurs in 
conjunction with increased blood volume and mean transit time, when compared with 
normal, or patients with relapsing remitting MS [96].  Increased blood volume is also 
observed in patients with clinically isolated syndrome and impaired executive function [112].  
 
Within the lesions themselves the haemodynamic picture is more complex.  Wuerfel and 
colleagues studied changes in perfusion at different stages of lesion development, including 
before the breakdown of the blood-brain barrier [113].  They found a significant increase in 
cerebral blood flow and blood volume both three weeks before, and during, the period of 
gadolinium leakage, and these measurements remained above baseline for the next several 
weeks.  Other studies have also noted enhanced perfusion in active lesions in which the 
blood-brain barrier is disturbed [99;114], as well as in ring enhancing lesions, where the 
increase is restricted to the lesion circumference [113].  The inclusion of active lesion data 
may explain the increased perfusion in studies of MS white matter mentioned above [94;95], 
and must be considered when interpreting global or regional measures of blood flow.  Most 
non-enhancing or chronic lesions show significantly reduced perfusion and blood volume 
[99;114].  Indeed, two of the lesions followed by Wuerfel et al. also developed reduced 
perfusion after several additional weeks [113], probably in response to tissue destruction 
during the inflamed period. 
 
Hypoperfusion occurs in conjunction with a slowing of flow, resulting in substantially 
prolonged cerebral circulation times [99] (but see also [103;113]).  In one study, the mean 
time in MS patients was 4.9 seconds (s.d. = 1.27 secs) versus 2.8 seconds (s.d. = 0.51 secs) in 
controls [115], and in another, the median longest time in MS was 6.47 seconds (range, 3.29-
29.24 seconds) versus 5.54 seconds in controls (range, 2.57-7.63 seconds; p <0.001) [116].  
In particular, it is the arterial flow which is slow, with prolonged arterial bolus arrival times 
[94;117] even in the presence of normal venous flow [117].  Slow arterial flow may be the 
result of raised circulating concentrations of the potent vasoconstrictive agent endothelin-1 
[118-122], which is raised in the cerebrospinal fluid of relapsing-remitting patients suffering 
acute clinical attacks, in comparison with those in a stable phase [123].  Lower than normal 
  
endothelin-1 concentrations have been reported in MS patients with non-active disease [124].  
Additionally, arteries in young people with MS have been found to have significantly less 
compliance (the ability to expand and recoil with pulsations) than normal [125], a deleterious 
phenomenon that also occurs in small vessel disease [126], diabetes, and hypertension, and 
which may help to explain the significant reductions in cerebrovascular reactivity observed in 
MS [127;128].  In MS, reduced flow may also be due to deficits in astrocytic β2-
adrenoceptors, which may impair astrocytic regulation of vessel tone and result in a 
chronically vasoconstricted state [119]. 
 
Several of the abnormalities reported in the brains of people with MS are also present in the 
retina, where it is possible to view blood flow directly, together with the dimensions of the 
vessels.  Here, reductions in blood flow volume and velocity have been observed in both 
retinal arteries and veins [129;130].  Most interestingly, even patients with no history of optic 
neuritis exhibit retinal arteries that are significantly thinner than normal, as well as 
significantly thicker venules [131] (see also [44]).  Such arterial thinning, perhaps due to 
constriction, coupled with venular widening, is consistent with many of the vascular 
observations of MS.  Perivenous sheathing has also been observed in optic neuritis [132], in a 
cohort where more than half the patients subsequently developed MS.  Given that the retina is 
devoid of myelin, the authors revived the possibility that venous pathology may be primary in 
MS (developing observations first made over 150 years ago [37]).   
 
In summary, a pattern emerges in MS of an overall reduction in cerebral blood flow, which 
nonetheless shows a local and temporary increase during lesion formation in response to local 
inflammation.  One interpretation is that the overall reduction in flow predisposes particular 
niches to hypoxia, and that the subsequent superimposition of additional impairments results 
in the focal degeneration of oligodendrocytes, consequent demyelination and generation of 
myelin breakdown products.  An inflammatory response, perhaps augmented by autoreactive 
lymphocytes, results in a temporary hyperaemia, which later resolves to a reduction in blood 
flow in response to tissue destruction. 
 
Other factors contributing to hypoxic damage 
In addition to aberrant haemodynamics, tissue hypoxia is also promoted by several other 
factors.  Inflammation, for example, can augment oxygen demand, reduce its supply, or raise 
the oxygen concentration threshold required for continued oxidative phosphorylation.  
Oxygen demand is increased by the recruitment of lymphocytes, which, unlike myeloid cells, 
primarily use oxidative phosphorylation for energy production (reviewed in [133]).  
Furthermore, substantial amounts of oxygen are consumed by the respiratory burst of 
activated neutrophils and microglia [134;135].  Inflammation can also promote dysfunctional 
vasoconstriction and leukocyte-capillary plugging, reducing capillary perfusion and tissue 
oxygenation [136].  Cells in inflammatory lesions additionally produce reactive oxygen and 
nitrogen species that are deleterious to normal mitochondrial function [137-141].  In 
particular, the prominent expression of NADPH oxidase and the inducible form of nitric 
oxide synthase (iNOS) can produce large quantities of the damaging free radicals superoxide 
and nitric oxide, and oxidative damage is prominent in MS lesions [139-141].  Additionally, 
nitric oxide competes with oxygen for the same binding site on mitochondrial cytochrome-c 
oxidase [142-147] thereby raising the Km for oxygen such that even normal oxygen 
concentrations become inadequate to maintain mitochondrial function.  Thus, nitric oxide can 
create a condition of ‘virtual hypoxia’ [148] that exacerbates the harmful effects of actual 
hypoxia on cell (e.g. oligodendrocyte) survival, even under conditions where either problem 
can be tolerated alone [149].  Widespread occurrences of virtual hypoxia are therefore one 
  
explanation for reduced oxygen utilisation of the MS brain [150].  In fact, the enhanced 
production of nitric oxide has been implicated in the pathogenesis of several demyelinating 
and neurodegenerative diseases [1;64;65;151-156].   
 
Evidence that the MS brain is indeed hypoxic 
There is substantial evidence that the MS brain is not only vulnerable to hypoxia, as 
described above, but that it is actually hypoxic.  Histological evidence of hypoxia includes 
the expression of hypoxia-related antigens [157-161], and the presence of lesions 
characterized by a Pattern III (hypoxia-like) type of demyelination.  This pattern of 
demyelination is similar to that found surrounding acute ischaemic lesions, and characterized 
by the preferential loss of myelin associated glycoprotein [81;162].  Furthermore, microarray 
analysis of normal appearing white matter from MS brains reveals the upregulation of genes 
induced by ischaemic preconditioning, including the upregulation of hypoxia inducible 
factor-1α and genes involved in vascular remodelling such as vascular endothelium derived 
growth factor (VEGF) receptor 1 [163;164].  More indirect evidence for hypoxia in MS 
includes a raised concentration of lactate within acute lesions, as assessed by magnetic 
resonance spectroscopy e.g. [165], and in cerebrospinal fluid [166;167].  Raised lactate 
suggests that insufficient oxygenation requires increased glycolysis.  Most convincingly, 
Yang and Dunn used frequency domain near-infrared spectroscopy to measure microvascular 
haemoglobin saturation in the brains of awake MS patients.  They found a significant 
relationship between saturation and clinical disability, and that 42% of oxygen saturation 
values were more than two times the standard deviation lower than the control mean [168].   
 
Vulnerability of oligodendrocytes to hypoxia 
Selective white matter damage is a common consequence of hypoxia [169-171], ischaemia 
[172-174], and inhibitors of mitochondrial oxidative phosphorylation [175-190].  Surviving 
energy limitation due to tissue hypoxia is a challenge for many cells, but in the white matter 
the major cell types faced with the problem are the axons, oligodendrocytes, astrocytes, 
microglia and endothelial cells.  At first thought, the most vulnerable components may be 
suspected to be the axons, but in fact Desai et al. [1] found that sustained hypoxia in an 
inflammatory environment selectively kills oligodendrocytes, resulting in primary Pattern III, 
hypoxia-like demyelination, as occurs in MS [4;81] (see also [191]).  Although the 
inflammatory environment included several toxic mediators such as superoxide and nitric 
oxide, the authors found that it was the hypoxia that was decisive in causing the 
demyelination: treatment with 80% oxygen during the 24 hours when the lesion was 
otherwise hypoxic either reduced the size of the lesion, or, in some cases, prevented the 
lesion from forming at all (figure 4) [1].  Perhaps oligodendrocytes succumb to hypoxia in 
preference to axons because they reside wholly within a hypoxic focus, whereas axons can be 
sustained by portions of their structure that lie in more hospitable locations.  Axons may also 
survive if they are selflessly sustained by the energy provided by oligodendrocytes [192-199] 
to their own fatal detriment.  Aside from providing metabolic support for axons, 
oligodendrocytes are also stressed by the substantial metabolic load of having to maintain 
numerous internodes of myelin [189;200].  Oligodendrocytes may also suffer, even at the 
earliest stages of demyelination, from some of the mitochondrial impairments that have been 
described in established multiple sclerosis lesions [201-205].  The special vulnerability of 
oligodendrocytes to hypoxic and metabolic stress is also illustrated by the fact that carbon 
monoxide poisoning, which systemically impairs both oxygen delivery (by reacting with 
haemoglobin and inducing hypotension) and mitochondrial function, selectively kills 
oligodendrocytes, resulting in Grinker’s myelinopathy [184;206] a week or more after 
exposure.  Astrocytes are less vulnerable to hypoxia because they have a robust capability for 
  
anaerobic glycolysis [207;208], and, together with microglia, do not consume as much 
oxygen as oligodendrocytes in hypoxic tissue [1].  Endothelial cells face less of a challenge 
due to their proximity to blood.   
 
Perhaps the simplest explanation for the susceptibility of oligodendrocytes to hypoxia is that 
their mitochondria are unable to maintain sufficient oxidative phosphorylation and ATP 
production under such conditions, but this possibility is undermined by the observation that 
adult myelinating oligodendrocytes can survive even when their normal mitochondrial 
function is impaired, at least if this change occurs progressively over time [193].  
Furthermore, adult human oligodendrocytes maintained in vitro are able to use aerobic 
glycolysis for the majority of their ATP production, an adaptation which should protect them 
from the deleterious effects of hypoxia [209].  Interestingly, in vitro observations suggest that 
oligodendrocytes are actually more vulnerable to a slowly developing hypoxia, as will occur 
in disease, than they are to anoxia [61].  This, and evidence of free radical-mediated lipid 
peroxidation [61], suggests that oxidative damage, more than failure of aerobic respiration, is 
the lethal underlying mechanism.  Alternatively, oligodendrocytes might also perish under 
hypoxic conditions following lethal H
+
-gated increases in intracellular calcium via TRPA1 
channels [210].  Oligodendrocytes are therefore particularly vulnerable to succumb to any of 
several factors [211], especially oxidative stress, and this vulnerability is attributable to their 
poor capacity to scavenge free radicals effectively and their radical-promoting large iron 
stores [212-218].  At first glance, it may appear surprising that oxidative stress should be a 
problem under hypoxic conditions, but oxidative damage can indeed result from hypoxic 
conditions [219], as well as from the more commonly recognized hyperoxic ones.   
 
The very common detection of MS lesions in the frontal and occipital horns of the lateral 
ventricles [18] could, at least in part, indicate that lesions at these locations fail to repair as 
well on MRI examination as lesions at other locations [18;20].  If so, the failure could be due 
to the especially high vulnerability to hypoxia of oligodendrocyte precursor cells [61;209].  
The demise of such cells at hypoxic foci would result in a shortage that would impede the 
repair of demyelination by remyelination.   
 
Pattern III Demyelination 
Different types, or patterns, of demyelination have been distinguished in MS lesions [4].  The 
type that characterizes the demyelination found in lesions described by different authors as 
the “initial”, “primary”, “primordial” or “prephagocytic” lesion [4;49;220-222] is the Pattern 
III type, also described as hypoxia-like demyelination [81].  Notably, Pattern III lesions form 
in the relative absence of T cells [49;220-225] although these cells are a prominent feature of 
autoimmune lesions, including those of the most commonly used animal model of MS, 
experimental autoimmune encephalomyelitis (EAE) [226].  An explanation for the lack of T 
cells may be found in the selective vulnerability of oligodendrocytes to hypoxia, and the 
widespread patchy distribution of hypoxia in the MS brain.  Thus rather than succumb to 
autoimmune attack, oligodendrocytes in these lesions may die due to insufficient oxygen.  
This death and ensuing demyelination may incite the later accumulation of T cells observed 
after the original insult [221;225;227].  Indeed, the demyelination may trigger an 
autoimmune response against myelin [228].  Thus the importance of hypoxia in causing 
demyelination in MS may currently be underestimated.  Large demyelinating lesions that are 
not centred on a vessel, such as Pattern III lesions [4], may be caused by hypoxia due to 
arterial inadequacy, whereas perivenular demyelination may be caused by hypoxia due to 
excessive venular oxygen desaturation.   
 
  
It will be apparent from the observations in this review that the ingredients required to form 
Pattern III demyelinating lesions can arise without the participation of acquired, autoreactive 
immune cells, such as T or B cells.  Whether Pattern III demyelinating lesions start to form in 
this way in MS, or whether the initial participation of acquired immune cells is essential in 
this disease, currently remains ambiguous, with observations favouring both interpretations.  
With either interpretation it seems likely that tissue hypoxia, promoted by the mechanisms 
outlined in this review, will play a key role in amplifying demyelination (and probably 
degeneration), whether or not it is responsible for initiating demyelination.   
 
A diagram summarising how different pathophysiological events can conspire to cause tissue 
hypoxia, and thereby demyelination, degeneration and loss of function, is shown in figure 5.  
 
Hyperbaric oxygen therapy in MS 
The realisation (above) that the inflamed CNS can be quite profoundly hypoxic, and that 
breathing raised oxygen concentrations can restore function [229] and prevent demyelination 
[1], raises the long-running and controversial issue of the value of hyperbaric oxygen (HBO) 
as a therapy in MS.  The therapy is conducted in pressure chambers, which may house 
several patients at a time, in which oxygen is breathed at raised pressure (e.g. 2 atmospheres), 
often for one hour.  The therapy is favoured mainly by patients, but usually treated with 
scepticism by clinicians.  The patients, who often pay for regular (e.g. weekly) sessions 
(“dives”), base their opinion on the benefit they experience in the days following a dive, often 
commenting on acute, temporary improvements in fatigue and bladder function in particular.  
Clinicians base their scepticism on a number of clinical trials, mainly conducted in the 1980s 
and now the subject of a Cochrane review [230;231] which noted “For example, the mean 
Expanded Disability Status Scale (EDSS) at 12 months was improved in the HBOT group 
(group mean reduction in EDSS compared to sham -0.85 of a point, 95% confidence interval 
-1.28 to -0.42, P = 0.0001).” but which concluded “At this time, the routine treatment of MS 
with [HBO] is not recommended.”, also commenting that the beneficial effects were 
“difficult to ascribe with biological plausibility”: in view of more recent knowledge, this 
opinion could be revised.   
 
The former clinical trials were mostly not designed to detect acute, temporary changes in 
symptoms, which may account for the different opinions of the efficacy of HBO between 
patients and clinicians.  From the perspective of current knowledge it is important to note that 
the clinical trials treated patients on an arbitrary timetable, rather than when the patients may 
have required oxygen to reverse ongoing hypoxia, and the trials also tended to include 
patients with long-standing disease, where marked improvements in response to therapy are 
perhaps less likely.  These considerations will have reduced the likelihood of uncovering 
positive therapeutic effects, at least with regard to the recent findings of acute hypoxia at the 
onset of new inflammatory and demyelinating lesions.  The new understanding is that it is 
patients with ongoing inflammatory lesions, such as occurs with relapsing remitting MS, who 
are most likely to benefit from oxygen, because it is these lesions that are likely to suffer 
from inadequate oxygenation.   
 
Whether oxygen at hyperbaric pressure is better, or worse, than, say, breathing 70% oxygen 
at normobaric pressure, remains untested, and theoretically uncertain.   
 
Regional Hypoxic Vulnerability in Other Diseases 
Notably, the periventricular white matter is vulnerable not only in SVD and MS, but also in a 
range of other disorders where impaired blood flow, energy compromise, or frank hypoxia 
  
are implicated [11].  Despite the varying aetiology and pathophysiological mechanisms 
involved, the similar anatomical involvement of the periventricular white matter suggests an 
inherent vulnerability of both this tissue, and the cells involved.    
 
In type 2 diabetes, reduced blood flow velocity in the middle cerebral artery, increased 
cerebrovascular resistance, and impaired vascular reactivity are significantly related to the 
volume of WMH on MRI [232].  The additional co-morbidity of hypertension worsens white 
matter damage in diabetes, and both conditions are associated with decreased retinal arterial 
diameter, suggesting reduced oxygen supply is a feature of both [233].  Notably, treatment of 
hypertension prevents the progression of white matter damage [234].  Abnormal blood flow 
(perhaps with a dysfunction of neurovascular coupling [235]), is also an important feature of 
migraine [236;237], and, again, migraine-associated lesions are prominent in the 
periventricular white matter [238;239].   
 
The leukodystrophy Krabbe’s disease is associated with a psychosine-mediated inhibition of 
mitochondrial complex IV [240-242] as well as extensive white matter pathology on MRI 
[243-245], and spectroscopic evidence of  axonal degeneration and myelin loss [244].  
Periventricular white matter lesions are also prominent in several disorders associated with 
mitochondrial impairment.  Leber’s hereditary optic neuropathy (LHON) is caused by a 
mitochondrial mutation [246], and the distribution of the lesions is similar to that in MS, with 
a preponderance in the periventricular white matter [247].  
 
Given the evidence presented above, an interesting consideration is whether exposure to 
hypoxia might induce white matter lesions in healthy and physically fit people, such as 
mountaineers.  Remarkably, climbing to over 7000 metres without supplemental oxygen is 
indeed associated with the presence of periventricular WMH [248], with new lesions 
emerging near the posterior horns of the lateral ventricles [249] or at other metabolically-
demanding watershed zones [250].  People who normally reside at high altitude have 
adaptations that limit their vulnerability to hypoxia.  
 
Therapeutic implications  
The observations discussed in this review suggest that parts of the periventricular white 
matter habitually rely on an oxygen supply that is only marginally higher than required to 
sustain normal function.  It follows that reductions in oxygen supply, or increases in demand, 
can erode this slim safety margin, rendering the tissue at risk of inadequate oxygenation.  If, 
and when, this happens the most vulnerable cells, the oligodendrocytes, will die first.  To 
prevent hypoxia, and thereby protect against the ensuing demyelination, imbalances between 
oxygen supply and demand must be avoided.  For a chronic condition like SVD, which can 
continue for decades in people who may show few if any symptoms, the most realistic 
therapeutic approach may be heightened vigilance to guard against conditions which impair 
oxygen delivery to the brain.  In MS, affected individuals are more easily distinguished, and 
vigilance to avoid hypoxia can be combined with existing therapies.   
 
This vigilance may include greater attention to stringently maintaining haemoglobin levels 
within the normal range, and perhaps the upper part of the normal range, as haemoglobin is 
reported to be significantly decreased in patients with MS [251], and anaemia more than 
doubles the risk of developing MS [252], and the risk of relapse [253] (see also [254]).  In 
this context, it is especially interesting that erythropoietin (which most notably boosts red cell 
production amongst a range of effects) improved outcome in both a pilot study in progressive 
MS, and a phase 2 trial in optic neuritis [255-257].  Common cardiovascular disorders, such 
  
as occur in obesity and diabetes, should also be combated to avoid vasculopathy and cerebral 
ischaemia, especially noting the higher prevalence of insulin resistance in MS patients than in 
healthy controls, and the association of both insulin resistance and adiposity with disability in 
the disease [258].  In this respect, it is noteworthy that the protective effect of simvastatin 
[259] in secondary progressive MS may be due in part to its suspected effects in 
counteracting vascular pathology.  The mechanism(s) underlying the beneficial effects of 
high dose biotin therapy in progressive MS [260] remain uncertain, but an enhancement of 
oxidative mitochondrial metabolism has been suggested [261].   
 
Patients might also benefit from close management of their arterial oxygen saturations, and 
more aggressive treatment of any underlying respiratory conditions, such as chronic 
obstructive pulmonary disease.  Lower arterial oxygen saturation, independent of 
confounders, correlates with more severe periventricular white matter lesions in non-
demented patients, as does co-incident chronic obstructive pulmonary disease [262].  
Similarly, infections, especially of the chest, should be promptly and effectively managed, as 
these can both impair normal gas exchange and promote the production of systemic pro-
inflammatory cytokines that might contribute to the pathological processes of SVD and MS.  
Advice to cease cigarette smoking may be especially worthwhile, as smoking is associated 
with the progression of both SVD [79;263] and MS [264;265].  Although the detrimental 
effects of smoking are complex and multifactorial, it is readily evident how pulmonary, 
cardiac, vascular and haematological components (e.g. enhanced carbon monoxide levels) 
can act to impair tissue oxygenation. 
 
While hypertension is a major risk factor for the progression of MS [266] and SVD [263], its 
counterpart, hypotension, is an important and often overlooked component of cerebral 
dysfunction that will nevertheless contribute to poor perfusion and hypoxia.  Decreases in 
diastolic pressure over time (as well as increases) double the risk of severe periventricular 
lesions [267].  Despite the classical notion that cerebral autoregulation is able to compensate 
systemic falls in pressure up to 60mmHg, hypotensive patients with pressures above this 
cutoff exhibit significantly reduced blood flow in their middle cerebral arteries, as well as 
impaired adjustments in flow to cognitive demands [268], making them at increased risk of 
periventricular demyelination.  Anti-hypertensive therapies, especially in patients with 
coincident SVD or MS, should therefore be managed carefully to avoid precipitous drops, 
with moderate and stable pressures becoming the end-goal of therapy: consideration should 
be given to treat even moderate hypotension in these patients, lest hypoperfusion should 
aggravate their pathology.   
 
In patients at risk of suffering white matter disease, these (and other) considerations in their 
day-to-day medical care will help to maintain ideal cerebral oxygenation and prevent disease 
progression. 
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Figure 1. Heat maps showing lesion distribution in MS, and their relationship with 
arterial watersheds.  (A) Coronal map of demyelinating MS lesions in postmortem brain, 
superimposed on a virtual brain section.  Upper inset: magnification showing the high 
frequency of lesions at the periventricular margin.  Adapted from (Haider et al., 2016).  
Lower inset: map showing the territories of the major cerebral arteries, indicating that the 
most common location of lesions coincides with the watershed between three major arteries.  
(B) Axial map of lesions detected by MRI in secondary progressive MS, superimposed on a 
T1-MRI template.  Adapted from Holland et al., 2012.  Circled region in B and C shows the 
correlation between the most frequent lesion location and the watershed territory between 
three major arteries.  ACA, anterior cerebral artery; LSA, lenticulostriate artery; MCA, 
middle cerebral artery; PCA, posterior cerebral artery.  Diagrams in A & B copyright 2011 by 
the American Society of Neuroimaging.   
  
  
 
 
 
Figure 2. Periventricular vasculature. Coronal radiograph of a hemisphere of the human 
brain vasculature filled with a radio-opaque marker (microplaque).  The larger vessels are 
veins, but note the long, fine end-arteries/arterioles penetrating from the brain surface 
towards the periventricular white matter.  Adapted from [23].   
  
  
 
 
 
Figure 3. Oxygen diffusion across arteries, arterioles and venules.  Confocal in vivo 
image of the cerebral cortex of an anaesthetized mouse showing the surface arteries and 
veins.  3A.  The inherent flavoprotein fluorescence (green) shows the distribution of 
functioning mitochondria a few minutes after breathing 10% oxygen instead of room air 
(21% oxygen).  It is only the mitochondria in a ‘halo’ around arteries that obtain sufficient 
oxygen for continued function, and the desaturated blood in the capillaries and veins is no 
longer able to support function: in animals breathing air the cortex shows a uniform green 
fluorescence.  Adapted from [270].  3B.  Similar images illustrating the same field and 
showing inherent flavoprotein fluorescence (left, green), and the applied, red potentiometic 
dye TMRM, which is accumulated in polarised (functioning) mitochondria (middle), with the 
merged image (right).  The mouse is again breathing 10% oxygen to make the brain hypoxic 
and thus reveal the provision of oxygen from the different vessels more clearly.  As in 3A, 
the arteries are surrounded by a halo showing that the FAD-positive mitochondria (green) are 
also polarised (red) and so capable of making ATP: the FAD and TMRM fluorescence are 
precisely superimposed.  The superimposition establishes that the FAD fluorescence is an 
accurate marker of functioning, polarised mitochondria.  The arrows distinguish a vein which 
is surrounded by a narrow halo of FAD- and TMRM-positive mitochondria, indicating that 
veins can also supply oxygen to tissue.   
  
  
 
Figure 4. Prevention of Pattern III demyelination by raised inspiratory oxygen. (A & B) 
Transverse sections through the spinal cord of two rats, taken at the level of an intraspinal 
(dorsal column) injection of lipopolysaccharide two weeks previously (stained for myelin, 
luxol fast blue/periodic acid–Schiff/hematoxylin): the area indicated at the base of the dorsal 
column is shown in more detail on the right.  A Pattern III demyelinating lesion (outlined 
with arrows) is visible in A, but the lesion fails to form in the animal shown in B, which was 
treated with 80% oxygen during the first two days post-injection, namely the time when the 
lesion site is otherwise hypoxic.  (C) Graph showing the area of demyelination in treated and 
untreated animals (***p<0.001).  Adapted from [1].  
  
  
 
 
Figure 5.  Diagram showing the relationships of some of the pathophysiological 
phenomena described in this review.   
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